These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31068371)

  • 1. Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells.
    Wu HW; Sheard MA; Malvar J; Fernandez GE; DeClerck YA; Blavier L; Shimada H; Theuer CP; Sposto R; Seeger RC
    Clin Cancer Res; 2019 Aug; 25(15):4761-4774. PubMed ID: 31068371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
    Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
    Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma.
    Barry WE; Jackson JR; Asuelime GE; Wu HW; Sun J; Wan Z; Malvar J; Sheard MA; Wang L; Seeger RC; Kim ES
    Clin Cancer Res; 2019 Jan; 25(1):325-333. PubMed ID: 30232225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in mice.
    Zobel MJ; Zamora AK; Wu HW; Sun J; Lascano D; Malvar J; Wang L; Sheard MA; Seeger RC; Kim ES
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2
    Chu Y; Nayyar G; Jiang S; Rosenblum JM; Soon-Shiong P; Safrit JT; Lee DA; Cairo MS
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy.
    Liu Y; Wu HW; Sheard MA; Sposto R; Somanchi SS; Cooper LJ; Lee DA; Seeger RC
    Clin Cancer Res; 2013 Apr; 19(8):2132-43. PubMed ID: 23378384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-15 Enhances Anti-GD2 Antibody-Mediated Cytotoxicity in an Orthotopic PDX Model of Neuroblastoma.
    Nguyen R; Moustaki A; Norrie JL; Brown S; Akers WJ; Shirinifard A; Dyer MA
    Clin Cancer Res; 2019 Dec; 25(24):7554-7564. PubMed ID: 31455682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-disialoganglioside antibody internalization by neuroblastoma cells as a mechanism of immunotherapy resistance.
    Tibbetts R; Yeo KK; Muthugounder S; Lee MH; Jung C; Porras-Corredor T; Sheard MA; Asgharzadeh S
    Cancer Immunol Immunother; 2022 Jan; 71(1):153-164. PubMed ID: 34043024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenretinide sensitizes multidrug-resistant human neuroblastoma cells to antibody-independent and ch14.18-mediated NK cell cytotoxicity.
    Shibina A; Seidel D; Somanchi SS; Lee DA; Stermann A; Maurer BJ; Lode HN; Reynolds CP; Huebener N
    J Mol Med (Berl); 2013 Apr; 91(4):459-72. PubMed ID: 23052481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small extracellular vesicles induce resistance to anti-GD2 immunotherapy unveiling tipifarnib as an adjunct to neuroblastoma immunotherapy.
    Liu X; Wills CA; Chen L; Zhang J; Zhao Y; Zhou M; Sundstrom JM; Schell T; Spiegelman VS; Young MM; Wang HG
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma.
    Nguyen R; Houston J; Chan WK; Finkelstein D; Dyer MA
    Cancer Immunol Immunother; 2018 Apr; 67(4):615-626. PubMed ID: 29327110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2
    Ly S; Anand V; El-Dana F; Nguyen K; Cai Y; Cai S; Piwnica-Worms H; Tripathy D; Sahin AA; Andreeff M; Battula VL
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment.
    Seitz CM; Flaadt T; Mezger M; Lang AM; Michaelis S; Katz M; Syring D; Joechner A; Rabsteyn A; Siebert N; Troschke-Meurer S; Zumpe M; Lode HN; Yang SF; Atar D; Mast AS; Scheuermann S; Heubach F; Handgretinger R; Lang P; Schlegel P
    Front Immunol; 2021; 12():690467. PubMed ID: 34367149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
    Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
    Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment.
    Martinez Sanz P; van Rees DJ; van Zogchel LMJ; Klein B; Bouti P; Olsman H; Schornagel K; Kok I; Sunak A; Leeuwenburg K; Timmerman I; Dierselhuis MP; Kholosy WM; Molenaar JJ; van Bruggen R; van den Berg TK; Kuijpers TW; Matlung HL; Tytgat GAM; Franke K
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049929
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
    Di Matteo S; Bilotta MT; Pelosi A; Haas D; Theinert T; Weber G; Schlegel PG; Berg M; Moretta L; Maggi E; Azzarone B; Vacca P; Tumino N; Caruana I
    Front Immunol; 2024; 15():1382931. PubMed ID: 38736882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating.
    Chen RL; Reynolds CP; Seeger RC
    Cancer Immunol Immunother; 2000 Feb; 48(11):603-12. PubMed ID: 10663607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of anti-GD2 Antibody-producing Mesenchymal Stem Cells as Cellular Immunotherapy.
    Iguchi M; Yagyu S; Kambe K; Higashi M; Fumino S; Kishida T; Iehara T; Mazda O; Tajiri T
    Anticancer Res; 2023 Jun; 43(6):2417-2424. PubMed ID: 37247922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
    Zirngibl F; Ivasko SM; Grunewald L; Klaus A; Schwiebert S; Ruf P; Lindhofer H; Astrahantseff K; Andersch L; Schulte JH; Lode HN; Eggert A; Anders K; Hundsdoerfer P; Künkele A
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34285106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dinutuximab for maintenance therapy in pediatric neuroblastoma.
    McGinty L; Kolesar J
    Am J Health Syst Pharm; 2017 Apr; 74(8):563-567. PubMed ID: 28389455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.